Cas:114-07-8 Erythromycin powder
| product name |
Erythromycin |
| cas number |
114-07-8 |
| apperance |
white powder |
| Density |
1.2±0.1 g/cm3 |
| MF |
C37H67NO13 |
| MW |
733.927 |
Erythromycin, clinically mainly used for tonsillitis caused by streptococcus, scarlet fever, diphtheria and carriers, gonorrhea, listeriosis, streptococcus pneumoniae lower respiratory tract infection (the above applies to penicillin intolerant patients for Legionella pneumonia and mycoplasma Pneumonia, this product can be used as the first choice medicine. It can still be used for upper respiratory tract infections caused by influenza bacillus, Staphylococcus aureus skin and soft tissue infections, syphilis, intestinal amebiasis, etc.
English name: Erythromycin
CAS Number: 114-07-8
Molecular formula: C37H67NO13
Molecular weight: 733.94
Accurate quality: 733.46100
PSA: 193.91000
LogP: 1.78560
Physical and chemical properties
Appearance and properties: white or milky white crystal or powder
Density: 1.2g/cm3
Melting point: 138-140ºC
Boiling point: 818.4ºC at 760mmHg
Flash point: 448.8ºC
Stability: stable under normal temperature and pressure
Storage conditions: 0-6ºC
Vapor pressure: 4.94E-31mmHg at 25°C
This product is a macrolide antibiotic, made from the culture broth of the actinomycete Streptomyces erythreus isolated from the soil on the island of Panay. It was first published by EliLilly in 1952. Several analogues such as erythromycin B and C are produced in the culture solution at the same time, and the difference in solvent solubility is used to remove them. This product is white or light yellow-white crystalline powder, odorless, bitter, hygroscopic in the air, soluble in ethanol, chloroform, acetone and ether, etc., slightly soluble in water. The solubility increases after salt formation. It is relatively stable in a dry state, and the aqueous solution is relatively stable under refrigeration, and the potency gradually decreases at room temperature. It is unstable when exposed to acid, and is relatively stable when slightly alkaline, and its potency is significantly reduced below pH 4. MP 135-140°C (decomposition), specific rotation -70~78° (2%, ethanol solution).
This product is suitable for neonatal sepsis, sepsis, and central nervous system infections caused by Pseudomonas aeruginosa, Proteus, Escherichia coli, Klebsiella, Enterobacter, Serratia Meningitis), urogenital infections, lung infections, biliary tract infections, abdominal infections and peritonitis, bone infections, burns, skin and soft tissue infections, acute and chronic otitis media, sinusitis, etc., or combined with other antibacterial drugs for staphylococcal infection (Methicillin-resistant strains are invalid). The product can be administered by intrathecal injection when used for Pseudomonas aeruginosa meningitis or ventriculitis; when used for bronchial and lung infections, the product can be inhaled as an adjuvant treatment. This product is ineffective against most group D streptococcal infections.
Audited Supplier 
){kind=link}
){kind=link}